HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roxana Dronca Selected Research

pembrolizumab

1/2021Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
12/2018Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
10/2018Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
10/2018Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
11/2017Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
12/2016Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
4/2016Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
1/2016Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
9/2014Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
7/2013Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Roxana Dronca Research Topics

Disease

11Melanoma (Melanoma, Malignant)
01/2021 - 07/2013
7Neoplasms (Cancer)
12/2023 - 07/2013
5Disease Progression
01/2020 - 07/2013
2Neoplasm Metastasis (Metastasis)
10/2018 - 01/2013
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
12/2023
1Lymphoma (Lymphomas)
12/2023
1Hematologic Neoplasms (Hematological Malignancy)
12/2023
1Leukemia
12/2023
1Interstitial Nephritis (Tubulointerstitial Nephritis)
01/2020
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2020
1Exanthema (Rash)
10/2019
1Fever (Fevers)
10/2019
1Familial Mediterranean Fever (Periodic Disease)
10/2019
1Fatigue
09/2014
1Carcinoma (Carcinomatosis)
05/2014
1Chronic Renal Insufficiency
05/2014
1Body Weight (Weight, Body)
07/2013
1Renal Cell Carcinoma (Grawitz Tumor)
01/2013

Drug/Important Bio-Agent (IBA)

10pembrolizumabIBA
01/2021 - 07/2013
4IpilimumabIBA
10/2018 - 07/2013
3Immune Checkpoint InhibitorsIBA
01/2020 - 07/2013
3B7-H1 AntigenIBA
10/2018 - 12/2016
1AntigensIBA
12/2023
1trametinibIBA
10/2019
1dabrafenibIBA
10/2019
1ColchicineFDA LinkGeneric
10/2019
1Mitogen-Activated Protein KinasesIBA
10/2019
1p38 Mitogen-Activated Protein KinasesIBA
10/2019
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
10/2018
1PlatinumIBA
08/2017
1Monoclonal AntibodiesIBA
04/2016
1Cisplatin (Platino)FDA LinkGeneric
05/2014
1Tyrosine Kinase InhibitorsIBA
01/2013

Therapy/Procedure

5Therapeutics
12/2023 - 01/2013
1Immunotherapy
01/2020
1Cystectomy
05/2014
1Neoadjuvant Therapy
05/2014
1Drug Therapy (Chemotherapy)
05/2014